Hosseini Farshad, Pitcher Ian, Kang Mehima, Mackay Martha, Singer Joel, Lee Terry, Madden Kenneth, Cairns John A, Wong Graham C, Fordyce Christopher B
Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Division of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
CJC Open. 2024 Apr 25;6(8):1004-1012. doi: 10.1016/j.cjco.2024.04.005. eCollection 2024 Aug.
Frailty is generally a marker of worse prognosis. The impact of frailty on both in-hospital and long-term outcomes in ST-segment-elevation myocardial infarction (STEMI) patients has not been well described. Given this context, we aimed to determine the prevalence and impact of frailty on in-hospital and 1-year outcomes in STEMI patients undergoing primary percutaneous coronary intervention (pPCI).
This retrospective study reviewed STEMI patients aged ≥ 65 years who underwent pPCI at 1 of the 2 pPCI-capable hospitals at Vancouver Coastal Health. A frailty index (FI) was determined using a deficit-accumulation model, with those with an FI > 0.25 being defined as frail. The primary outcome was 1-year all-cause mortality. The secondary outcomes included in-hospital all-cause mortality, a composite of adverse in-hospital outcomes (all-cause mortality, cardiogenic shock, heart failure, reinfarction, major bleeding, or stroke), and the individual components of the composite.
A total of 1579 patients were reviewed, of which 228 (14.4%) were determined to be frail. After multivariable adjustment, greater frailty (ie, increasing FI) was associated with increased in-hospital all-cause mortality (odds ratio [OR], 1.88; 95% confidence interval [CI], 1.50-2.35, < 0.001), the composite adverse in-hospital outcome (OR, 1.46; 95% CI, 1.27-1.68, < 0.001), and 1-year all-cause mortality (OR, 1.48; 95% CI, 1.10-2.00, = 0.011).
In a contemporary STEMI cohort of older patients receiving pPCI, 1 in 7 patients were frail, with greater frailty being independently associated with increased in-hospital and long-term adverse outcomes. These findings highlight the need for the early recognition of frailty and implementation of an interdisciplinary approach toward the management of frail STEMI patients.
衰弱通常是预后较差的一个标志。衰弱对ST段抬高型心肌梗死(STEMI)患者住院期间及长期预后的影响尚未得到充分描述。在此背景下,我们旨在确定衰弱在接受直接经皮冠状动脉介入治疗(pPCI)的STEMI患者中的患病率及其对住院期间和1年预后的影响。
这项回顾性研究纳入了温哥华沿海卫生区两家具备pPCI能力的医院中年龄≥65岁且接受pPCI的STEMI患者。使用缺陷积累模型确定衰弱指数(FI),FI>0.25的患者被定义为衰弱。主要结局是1年全因死亡率。次要结局包括住院期间全因死亡率、住院期间不良结局的复合指标(全因死亡率、心源性休克、心力衰竭、再梗死、大出血或中风)以及该复合指标的各个组成部分。
共纳入1579例患者,其中228例(14.4%)被确定为衰弱。多变量调整后,更高程度的衰弱(即FI增加)与住院期间全因死亡率增加相关(比值比[OR],1.88;95%置信区间[CI],1.50 - 2.35,P<0.001)、住院期间不良结局的复合指标(OR,1.46;95%CI,1.27 - 1.68,P<0.001)以及1年全因死亡率(OR,1.48;95%CI,1.10 - 2.00,P = 0.011)。
在当代接受pPCI的老年STEMI队列中,每7例患者中有1例衰弱,更高程度的衰弱与住院期间及长期不良结局增加独立相关。这些发现凸显了早期识别衰弱并对衰弱的STEMI患者实施跨学科管理方法的必要性。